Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
Mohammed Tag-Adeen,1,2 Ahlam Mohamed Sabra,1 Yuko Akazawa,2 Ken Ohnita,2 Kazuhiko Nakao2 1Department of Internal Medicine, Qena School of Medicine, South Valley University, Qena, Egypt; 2Department of Gastroenterology and Hepatology, Nagasaki School of Biomedical Sciences, Nagasaki University, Nagas...
Guardado en:
Autores principales: | Tag-Adeen M, Sabra AM, Akazawa Y, Ohnita K, Nakao K |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/53512dde699d4245be9ecda2c39ede78 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
por: Elabd NS, et al.
Publicado: (2021) -
FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran
por: Behnaz Amernia, et al.
Publicado: (2021) -
Approaches to the Diagnosis of Portal Hypertension: Non-Invasive or Invasive Tests?
por: Dajti E, et al.
Publicado: (2021) -
Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain
por: Abdulla MA, et al.
Publicado: (2017) -
Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Vicente Soriano, et al.
Publicado: (2022)